La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Luye Pharma Group Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Dian Bo Liu

Amministratore delegato

CN¥4.2m

Compenso totale

Percentuale dello stipendio del CEO	75.1%
Mandato del CEO	21.1yrs
Proprietà del CEO	n/a
Durata media del management	12.6yrs
Durata media del Consiglio di amministrazione	10.2yrs

Aggiornamenti recenti sulla gestione

We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed

May 21

Recent updates

Luye Pharma Group Ltd.'s (HKG:2186) Earnings Haven't Escaped The Attention Of Investors

Jun 19

We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed

May 21

Luye Pharma Group Ltd.'s (HKG:2186) Intrinsic Value Is Potentially 20% Below Its Share Price

Aug 17

Is Luye Pharma Group (HKG:2186) Using Too Much Debt?

May 10

We Think Luye Pharma Group (HKG:2186) Is Taking Some Risk With Its Debt

Sep 20

Time To Worry? Analysts Just Downgraded Their Luye Pharma Group Ltd. (HKG:2186) Outlook

Apr 06

Luye Pharma Group's (HKG:2186) Shareholders Are Down 31% On Their Shares

Mar 17

A Closer Look At Luye Pharma Group Ltd.'s (HKG:2186) Impressive ROE

Feb 19

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Dian Bo Liu rispetto agli utili di Luye Pharma Group?
Data	Compenso totale	Stipendio	Guadagni aziendali
Dec 31 2023	CN¥4m	CN¥3m	CN¥533m
Sep 30 2023	n/a	n/a	CN¥495m
Jun 30 2023	n/a	n/a	CN¥458m
Mar 31 2023	n/a	n/a	CN¥531m
Dec 31 2022	CN¥3m	CN¥3m	CN¥605m
Sep 30 2022	n/a	n/a	CN¥190m
Jun 30 2022	n/a	n/a	-CN¥224m
Mar 31 2022	n/a	n/a	-CN¥179m
Dec 31 2021	CN¥4m	CN¥3m	-CN¥134m
Sep 30 2021	n/a	n/a	CN¥210m
Jun 30 2021	n/a	n/a	CN¥554m
Mar 31 2021	n/a	n/a	CN¥630m
Dec 31 2020	CN¥5m	CN¥4m	CN¥707m
Sep 30 2020	n/a	n/a	CN¥955m
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥1b
Dec 31 2019	CN¥4m	CN¥3m	CN¥1b
Sep 30 2019	n/a	n/a	CN¥1b
Jun 30 2019	n/a	n/a	CN¥1b
Mar 31 2019	n/a	n/a	CN¥1b
Dec 31 2018	CN¥4m	CN¥3m	CN¥1b
Sep 30 2018	n/a	n/a	CN¥1b
Jun 30 2018	n/a	n/a	CN¥1b
Mar 31 2018	n/a	n/a	CN¥1b
Dec 31 2017	CN¥4m	CN¥3m	CN¥981m

Compensazione vs Mercato: La retribuzione totale di Dian Bo ($USD 585.65K ) è circa la media per le aziende di dimensioni simili nel mercato Hong Kong ($USD 629.60K ).

Compensazione vs guadagni: La retribuzione di Dian Bo è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Dian Bo Liu (58 yo)

21.1yrs

Mandato

CN¥4,180,000

Compensazione

Mr. Dian Bo Liu is a Co-Founder of Luye Pharma Group Ltd. in 1994 and serves as its Head of Corporate Directions & Strategies and has been its Chief Executive Officer since July 2003. Mr. Liu is responsibl...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Dian Bo Liu	Co-Founder	21.1yrs	CN¥4.18m	Nessun dato
Rong Bing Yang	Co-Founder & Vice Executive Chairman	21.1yrs	CN¥3.09m	Nessun dato
Hui Xian Yuan	Co-Founder & Executive Director	no data	CN¥1.46m	Nessun dato
Yuan Yuan Zhu	Executive Director	no data	CN¥1.50m	Nessun dato
Yuan Chong Liu	Chief Financial Officer	12.6yrs	Nessun dato	Nessun dato
Mei Yi Lee	Company Secretary	3.7yrs	Nessun dato	Nessun dato

12.6yrs

Durata media

58yo

Età media

Gestione esperta: Il team dirigenziale di 2186 è esperto e expertise (durata media dell'incarico 12.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Dian Bo Liu	Co-Founder	21.1yrs	CN¥4.18m	Nessun dato
Rong Bing Yang	Co-Founder & Vice Executive Chairman	21.1yrs	CN¥3.09m	Nessun dato
Hui Xian Yuan	Co-Founder & Executive Director	21.1yrs	CN¥1.46m	Nessun dato
Yuan Yuan Zhu	Executive Director	10.4yrs	CN¥1.50m	Nessun dato
Yuk Lam Lo	Independent Non-Executive Director	10.2yrs	CN¥269.00k	Nessun dato
Man Kit Leung	Independent Non-Executive Director	10.2yrs	CN¥322.00k	Nessun dato
Rui Lin Song	Non-Executive Director	7.4yrs	CN¥269.00k	Nessun dato
Sze Chung Choy	Independent Non-Executive Director	10.2yrs	CN¥269.00k	Nessun dato
Huaqiao Zhang	Independent Non-Executive Director	10.2yrs	CN¥269.00k	Nessun dato
Dong Lyu	Non-Executive Director	less than a year	Nessun dato	Nessun dato
Lian Xia	Independent Non-Executive Director	1.3yrs	CN¥162.00k	Nessun dato

10.2yrs

Durata media

61yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 2186 è composto da personale esperto e esperto (durata media dell'incarico 10.2 anni).

Luye Pharma Group Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed

Luye Pharma Group Ltd., Annual General Meeting, May 28, 2024

Luye Pharma Group Ltd. Announces Board Changes

Luye Pharma Group Ltd. Appoints XIA Lian as an Independent Non-Executive Director

Less than half of directors are independent

Luye Pharma Group Ltd., Annual General Meeting, Jun 20, 2022

Recent updates

Luye Pharma Group Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (Paliperidone Palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder

Shenzhen Luye Private Equity Investment Fund Partnership (Limited Partnership) managed by Shenzhen Investment Holding Capital Co., Ltd. agreed to acquire 25% stake in Nanjing Luye Pharmaceutical Co., Ltd. from Luye Pharma Group Ltd. (SEHK:2186) for CNY 1.0 billion.

Luye Pharma Group Ltd. Announces Approval of New Analgesic Product Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) for Marketing in China

Luye Pharma Group Ltd.'s (HKG:2186) Earnings Haven't Escaped The Attention Of Investors

Luye Pharma Group Ltd. Announces Approval of Meibirui (Paliperidone Palmitate Injection) for Marketing in China

We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed

Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden

Now 20% overvalued

Now 23% overvalued

Full year 2023 earnings: EPS misses analyst expectations

Luye Pharma Group Ltd., Annual General Meeting, May 28, 2024

Luye Pharma Group Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao

Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610

Is Luye Pharma Group Ltd. (HKG:2186) Trading At A 27% Discount?

Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension (Ly03010) in the United States

Now 20% undervalued after recent price drop

Some Confidence Is Lacking In Luye Pharma Group Ltd.'s (HKG:2186) P/S

Investor sentiment deteriorates as stock falls 17%

Luye Pharma Group (HKG:2186) Takes On Some Risk With Its Use Of Debt

Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong

Luye Pharma Group Ltd. Announces Board Changes

A Look At The Fair Value Of Luye Pharma Group Ltd. (HKG:2186)

Luye Pharma Group Ltd. Submits New Drug Application to the U.S. Food and Drug Administration Through the 505(B)(2) Pathway for Paliperidone Palmitate Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder

First half 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 16%

Is Luye Pharma Group (HKG:2186) A Risky Investment?

Luye Pharma Group Ltd. Announces the Innovative Formulation, Goserelin Microspheres for Injection Approved by the National Medical Products Administratio

First half 2023 earnings released: EPS: CN¥0.041 (vs CN¥0.085 in 1H 2022)

Luye Pharma Group Ltd. Submits New Drug Application for Lurbinectedin

Luye Pharma Group Ltd. Announces the First Batch of Rykindo for Extended-Release Injectable Suspension for Export to the United States

Luye Pharma Group Ltd.'s (HKG:2186) Intrinsic Value Is Potentially 20% Below Its Share Price

Luye Pharma Group Ltd. Completes Patient Enrollment for the Phase 2 Clinical Trial of New Class 1 Drug LY03014 in China

Luye Pharma Group Ltd. Announces National Medical Products Administration of People's Republic of China Approves its Goserelin Microspheres for Injection for Treatment of Prostate Cancer for Patients Requiring Androgen Deprivation Therapy

Luye Pharma Group Ltd. Announces Marketing Registration of Xuezhikang Approved in Uzbekistan

Luye Pharma Group Ltd Announces Acceptance of the NDA for Lurbinectedin by NMPA in China

Luye Pharma Group Ltd. Appoints XIA Lian as an Independent Non-Executive Director

Is Luye Pharma Group (HKG:2186) Using Too Much Debt?

Consensus EPS estimates fall by 11%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Luye Pharma Group Ltd. Announces Approval Obtained for Initiating Clinical Trial in China for the 3-Month Dosing Form of Goserelin Acetate Extended-Release Microspheres for Injection (LY01022)

FDA Approves Luye Pharma's Rykindo for the Treatment of Schizophrenia and Bipolar 1 Disorder

Luye Pharma Group Ltd. Announces the Acceptance of Marketing Application of Paliperidone Palmitate Injection (LY03010)

Luye Pharma Group Ltd. Announces First Patient Dosed in Phase II Clinical Study in China for New Class 1 Drug LY03014

Luye Pharma Group Ltd. Announces the Pivotal Study Conducted in the U.S. in Respect of the Group's New Product Candidate

Less than half of directors are independent

Luye Pharma Group Ltd. Announces Marketing Registration of Class 1 Innovative Antidepressant Ruoxinlin (Ly03005) Approved by NMPA

Luye Pharma Group Ltd. announced that it expects to receive CNY 300 million in funding

First half 2022 earnings released: EPS: CN¥0.085 (vs CN¥0.11 in 1H 2021)

Luye Pharma Group Ltd. to Report Q2, 2022 Results on Aug 29, 2022

Luye Pharma Group Ltd. Announces New Drug Application for New Indication of Goserelin Acetate Extended-Release Microspheres for Injection (LY01005) for Breast Cancer Has Been Accepted in China

Luye Pharma Group Ltd. Announces Phase III Clinical Trial of Rotigotine

Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin (LY01017) Approves for Urgent Clinical Use in Hainan

Luye Pharma Group Ltd. Announces Dulaglutide Injection BA5101 Entered into Phase III Clinical Trial in China

Luye Pharma Group Ltd. Announces Results of A Phase III Clinical Trial of Class 1 New Drug Ly03005 Presented At the 2022 APA Annual Meeting

Luye Pharma Group Ltd. Announces Results of A Phase I Clinical Trial of Lurbinectedin as Second-Line Therapy in Chinese Patients with SCLC Presented At the 2022 Asco Annual Meeting

Luye Pharma Group Ltd., Annual General Meeting, Jun 20, 2022

Luye Pharma Group Ltd. Announces Completion of Phase I Clinical Trial for Class 1 New Drug LY03014 in China

Full year 2021 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Luye Pharma Group Ltd. Submits a New Drug Application for Lurbinectedin (LY01017) for Injection

Luye Pharma Group Ltd. Announces New Indications Approved for Boyounuo® (Bevacizumab Injection) in China

Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trials for Monthly Microsphere Injection New Drug LY03009 for Parkinson's Disease in the United States

Luye Pharma Group Ltd. Announces Acceptance of Application for Marketing Authorization in China for Goserelin Acetate Extended-Release Microspheres for Injection (LY01005)

Luye Pharma Group Releases Top-Line Results from A Phase II Clinical Trial of Its New Antidepressant Ansofaxine Hydrochloride Extended-Release Tablets

Luye Pharma Group Ltd. Obtains Approval for Initiating Clinical Trial for Group\U0027s Innovative Antibody Drug BA1201 in China